ENTX - エンテラ・バイオ (Entera Bio Ltd.) エンテラ・バイオ

 ENTXのチャート


 ENTXの企業情報

symbol ENTx
会社名 Entera Bio Ltd (エンテラ・バイオ)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Entera Bio Ltd is an Israel-based product-focused biotechnology company that specializes in the oral delivery of large molecules and biologics. The Company conducts clinical trials on its proprietary technology which allows oral delivery of large molecules and biologics while enhancing their absorption in the gastrointestinal (GI) tract. Entera Bio Ltd's technology addresses the major problems of oral drug delivery of large molecule active pharmaceutical ingredients (APIs). Most large molecules cannot be administered orally as they are not readily absorbed by the gastrointestinal tract and are rapidly degraded by a myriad of enzymes and acids in the gastrointestinal tract. The Company’s proprietary technologies act synergistically to transport and protect large molecules. The Company develops drugs for hypoparathyroidism osteoporosis and bone healing.  エンテラ・バイオはイスラエルのバイオ医薬品企業。有効な治療法が確立されていない疾患のための治療薬の発見、開発および商品化に焦点を当て事業を行う。主に副甲状腺機能低下症および骨粗しょう症の治療薬として経口カプセルの開発を手掛ける。主要製品候補には、副甲状腺ホルモンの治療薬EB612や、骨粗しょう症および癒着不能骨折の治療薬EB613などがある。   Entera is a leader in the development of orally delivered large molecule therapeutics for use in areas with significant unmet medical need where adoption of injectable therapies is limited due to cost, convenience and compliance challenges for patients. The Company's proprietary, oral drug delivery technology is designed to address the technical challenges of poor absorption, high variability, and the inability to deliver large molecules to the targeted location in the body through the use of a synthetic absorption enhancer to facilitate the absorption of large molecules, and protease inhibitors to prevent enzymatic degradation and support delivery to targeted tissues. The Company's most advanced product candidates, EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are in Phase 2 clinical development. Entera also licenses its technology to biopharmaceutical companies for use with their proprietary compounds and, to date, has established a collaboration with Amgen Inc.
本社所在地 Kiryat Hadassah Minrav Building - Fifth Floor Jerusalem 9112002 ISR
代表者氏名 Gerald M. Lieberman ジェラルド・M・リーバーマン
代表者役職名 Chairman of the Board 取締役会会長
電話番号
設立年月日 40330
市場名 NASDAQ Small Cap
ipoyear 2018年
従業員数
url www.enterabio.com
nasdaq_url https://www.nasdaq.com/symbol/entx
adr_tso
EBITDA EBITDA(百万ドル) -12.65700
終値(lastsale) 5.85
時価総額(marketcap) 66855672
時価総額 時価総額(百万ドル) 60.11296
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 88.47196
当期純利益 当期純利益(百万ドル) -10.02400
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Entera Bio Ltd revenues was not reported. Net loss decreased 31% to $2.6M. Lower net loss reflects FV Adjustments of Financial Investments increase from $479K to $2.9M (income) GENERAL AND ADMINISTRATIVE EXPENSES (INC decrease of 70% to $854K (expense) Other financial expenses (income) net increase from $71K (expense) to $23K (income).

 ENTXのテクニカル分析


 ENTXのニュース

   Parathyroid Hormone Global Market Report 2021: COVID-19 Growth And Change To 2030  2021/09/27 11:35:00 Intrado Digital Media
Major players in the parathyroid hormone market are Pfizer Inc, Eli Lilly and Company, Radius Health Inc, Shire, Ascendis Pharma, Entera Bio Ltd. , and Extend Biosciences Inc. The global parathyroid hormone market is expected to grow from $1. Major players in the parathyroid hormone market are Pfizer Inc, Eli Lilly and Company, Radius Health Inc, Shire, Ascendis Pharma, Entera Bio Ltd. , and Extend Biosciences Inc. The global parathyroid hormone market is expected to grow from $1.
   Entera Bio Selected for Late Breaking Oral Presentation of Phase 2 6-Month Osteoporosis Data at ASBMR 2021 Annual Meeting  2021/09/01 12:30:00 Intrado Digital Media
Second of Two Presentations to be Delivered by Entera
   Knoll Capital Management, LLC Buys Entera Bio, Annovis Bio Inc, Advanced Micro Devices Inc  2021/08/24 19:38:17 GuruFocus
Related Stocks: ENTX , SVM , SILV , ANVS , AMD , AGTC ,
   Entera Bio to Conduct Annual Shareholders Meeting on October 4, 2021  2021/08/23 15:00:00 Intrado Digital Media
BOSTON and JERUSALEM, Aug. 23, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced it will host its annual shareholders meeting on Monday, October 4, 2021.
   Entera Bio to Present at H.C. Wainwright 23rd Annual Global Investment Conference  2021/08/23 12:30:00 Intrado Digital Media
BOSTON and JERUSALEM, Aug. 23, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced the Companys CEO Spiros Jamas will present at the H.C. Wainwright 23rd Annual Global Investment Conference on Monday, September 13, 2021 at 3:30 pm ET at the Lotte New York Palace Hotel. The hybrid in-person and virtual conference will take place from September 1315, 2021. In addition to the presentation, management will conduct 1-on-1 meetings with investors. For more information on the conference or to register, visit: HCW Events .
   Entera Bio Selected for Late Breaking Oral Presentation of Phase 2 6-Month Osteoporosis Data at ASBMR 2021 Annual Meeting  2021/09/01 12:30:00 Intrado Digital Media
Second of Two Presentations to be Delivered by Entera
   Knoll Capital Management, LLC Buys Entera Bio, Annovis Bio Inc, Advanced Micro Devices Inc  2021/08/24 19:38:17 GuruFocus
Related Stocks: ENTX , SVM , SILV , ANVS , AMD , AGTC ,
   Entera Bio to Conduct Annual Shareholders Meeting on October 4, 2021  2021/08/23 15:00:00 Intrado Digital Media
BOSTON and JERUSALEM, Aug. 23, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced it will host its annual shareholders meeting on Monday, October 4, 2021.
   Entera Bio to Present at H.C. Wainwright 23rd Annual Global Investment Conference  2021/08/23 12:30:00 Intrado Digital Media
BOSTON and JERUSALEM, Aug. 23, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced the Companys CEO Spiros Jamas will present at the H.C. Wainwright 23rd Annual Global Investment Conference on Monday, September 13, 2021 at 3:30 pm ET at the Lotte New York Palace Hotel. The hybrid in-person and virtual conference will take place from September 1315, 2021. In addition to the presentation, management will conduct 1-on-1 meetings with investors. For more information on the conference or to register, visit: HCW Events .
   Entera Bio Ltd. (ENTX) CEO Spiros Jamas on Q2 2021 Results - Earnings Call Transcript  2021/08/16 17:45:04 Seeking Alpha
   Knoll Capital Management, LLC Buys Entera Bio, Annovis Bio Inc, Advanced Micro Devices Inc  2021/08/24 19:38:17 GuruFocus
Related Stocks: ENTX , SVM , SILV , ANVS , AMD , AGTC ,
   Entera Bio to Conduct Annual Shareholders Meeting on October 4, 2021  2021/08/23 15:00:00 Intrado Digital Media
BOSTON and JERUSALEM, Aug. 23, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced it will host its annual shareholders meeting on Monday, October 4, 2021.
   Entera Bio to Present at H.C. Wainwright 23rd Annual Global Investment Conference  2021/08/23 12:30:00 Intrado Digital Media
BOSTON and JERUSALEM, Aug. 23, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced the Companys CEO Spiros Jamas will present at the H.C. Wainwright 23rd Annual Global Investment Conference on Monday, September 13, 2021 at 3:30 pm ET at the Lotte New York Palace Hotel. The hybrid in-person and virtual conference will take place from September 1315, 2021. In addition to the presentation, management will conduct 1-on-1 meetings with investors. For more information on the conference or to register, visit: HCW Events .
   Entera Bio Ltd. (ENTX) CEO Spiros Jamas on Q2 2021 Results - Earnings Call Transcript  2021/08/16 17:45:04 Seeking Alpha
   Entera Bio Reports Second Quarter 2021 Financial Results and Provides Clinical Updates  2021/08/16 10:30:00 Intrado Digital Media
Phase 2 EB613 Clinical Trial in Osteoporosi s Achieves 6-month Bone Mineral Density Endpoint; Primary and Key Secondary Endpoints Met

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 エンテラ・バイオ ENTX Entera Bio Ltd.)

 twitter  (公式ツイッターやCEOツイッターなど)